Feghaly Julien, Al Hout Abdul Rahman, Mercieca Balbi Mattew
St George's, University of London, London, UK.
Department of Cardiology, Mater Dei Hospital, Msida, Malta.
BMJ Case Rep. 2017 Oct 9;2017:bcr-2017-220483. doi: 10.1136/bcr-2017-220483.
The use of aspirin, as part of a dual antiplatelet therapy regimen, is an established standard following coronary stenting in patients suffering from acute coronary syndrome (ACS). However, in glucose-6-phosphate dehydrogenase (G6PD) deficient patients, precaution is always taken with aspirin use, due to the risk of haemolysis. We reviewed all previous cases of G6PD deficient patients with ACS, in addition to a review of the available literature, to better understand the safety of aspirin use in this population. To date, there are no reported cases of haemolysis following aspirin use in this patient group and no guideline is established to date.
作为双联抗血小板治疗方案的一部分，使用阿司匹林是急性冠状动脉综合征（ACS）患者冠状动脉支架置入术后的既定标准。然而，在葡萄糖-6-磷酸脱氢酶（G6PD）缺乏的患者中，由于存在溶血风险，使用阿司匹林时总是要谨慎。我们回顾了既往所有G6PD缺乏的ACS患者病例，并查阅了现有文献，以更好地了解该人群使用阿司匹林的安全性。迄今为止，尚无该患者群体使用阿司匹林后发生溶血的报告病例，且目前尚未制定相关指南。
